Clinical Trial Update: Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

Pilot dose-escalation trial evaluating canakinumab (ILARIS) in Duchenne muscular dystrophy; Phase 1/2, status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Canakinumab (canakinumab)
• ILARIS (canakinumab)

Snippet

Sponsor: Children's National Research Institute | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: UNKNOWN